Alzheimer鈥檚 disease is the most common form of neurodegenerative disease, estimated to contribute to 60鈥�70% of all cases of dementia worldwide. Increasing evidence suggests that neuroinflammation, primarily mediated by microglia, contributes to the onset and progression of Alzheimer鈥檚 disease. Hence, microglia are considered a major therapeutic target that could potentially yield effective disease-modifying treatments for Alzheimer鈥檚 disease. However, despite the interest in studying microglia as Alzheimer鈥檚 disease drug targets, the lack of accurate, consistent, and scalable microglial cellular models hinders drug discovery and development.

In this GEN webinar, hear from our distinguished expert, Dr Matthias Pawlowski, and learn about the emerging role of microglia in the pathogenesis of Alzheimer鈥檚 disease and their potential as a therapeutic target to treat this disease effectively. Additionally, Dr Malathi Raman will present data on the validation of 91探花鈥檚 hiPSC-derived ioMicroglia cells as a potential human-based cellular model for Alzheimer鈥檚 disease research and drug development, including the expression of specific markers (TMEM119, P2RY12, IBA1), key phagocytic & cytokine secretion functions, and co-culture compatibility with glutamatergic neurons.

For accessing webinar, please fill out the form below.